In:
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Vol. 42, No. 9 ( 1998-09), p. 2326-2331
Abstract:
Rapid, quantitative, and objective determination of the susceptibilities of human cytomegalovirus (HCMV) clinical isolates to ganciclovir has been assessed by an assay that uses a fluorochrome-labeled monoclonal antibody to an HCMV immediate-early antigen and flow cytometry. Analysis of the ganciclovir susceptibilities of 25 phenotypically characterized clinical isolates by flow cytometry demonstrated that the 50% inhibitory concentrations (IC 50 s) of ganciclovir for 19 of the isolates were between 1.14 and 6.66 μM, with a mean of 4.32 μM (±1.93) (sensitive; IC 50 less than 7 μM), the IC 50 s for 2 isolates were 8.48 and 9.79 μM (partially resistant), and the IC 50 s for 4 isolates were greater than 96 μM (resistant). Comparative analysis of the drug susceptibilities of these clinical isolates by the plaque reduction assay gave IC 50 s of less than 6 μM, with a mean of 2.88 μM (±1.40) for the 19 drug-sensitive isolates, IC 50 s of 6 to 8 μM for the partially resistant isolates, and IC 50 s of greater than 12 μM for the four resistant clinical isolates. Comparison of the IC 50 s for the drug-susceptible and partially resistant clinical isolates obtained by the flow cytometry assay with the IC 50 s obtained by the plaque reduction assay showed an acceptable correlation ( r 2 = 0.473; P = 0.001), suggesting that the flow cytometry assay could substitute for the more labor-intensive, subjective, and time-consuming plaque reduction assay.
Type of Medium:
Online Resource
ISSN:
0066-4804
,
1098-6596
DOI:
10.1128/AAC.42.9.2326
Language:
English
Publisher:
American Society for Microbiology
Publication Date:
1998
detail.hit.zdb_id:
1496156-8
SSG:
12
SSG:
15,3
Bookmarklink
